Venture capital firm Sequoia Capital China has led the $50-million Series C fundraising round in Adagene, a Chinese antibody discovery and development firm based in Suzhou, according to an announcement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
